Venezuela using coronavirus as cover to crack down on dissent, report claims
A report from Human Rights Watch was featured among the site’s world news headlines.
Read MoreLive world news related to the coronavirus (COVID-19) pandemic, updated by the minute. Follow global developments, statistics, and selected cryptocurrency news.
Read international coverage of the coronavirus pandemic and related global events.
Explore News
Visit the statistics section for data related to the coronavirus pandemic.
View Stats
Stay oriented with the site’s described live update format.
Read updates
A report from Human Rights Watch was featured among the site’s world news headlines.
Read More
The site featured this headline in its world news coverage.
Read More
The article covered the beginning of arguments by phone during the pandemic.
Read More
The site reported on the WHO chief’s self-quarantine after contact with a person who tested positive.
Read More
The site published an article discussing possible smartphone data sharing.
Read More
The site published an article on the initiative described in the headline.
Read More
The site discussed the subject of hoax martial law emails in a coronavirus article.
Read MoreLong COVID patients are reporting improvement after experimental stem cell treatment, providing a promising signal for people living with prolonged symptoms following COVID-19. Accounts describe reduced exhaustion, easier breathing and sharper thinking following cell-based therapy, outcomes that have eluded many standard treatments.
Those reports remain encouraging rather than conclusive. Long COVID, also called post-acute sequelae of COVID-19 or post-COVID condition, varies considerably between patients, and individual improvements do not establish that a procedure is responsible. Questions about the type of cells, manufacturing standards, dosage, follow-up periods and long-term safety will determine whether the approach becomes a credible treatment.
Long COVID is not a single condition. Some people are primarily affected by post-exertional malaise, while others experience cognitive impairment, chronic cough, headaches, sleep disturbance or orthostatic intolerance. Comparing experimental therapy with established supportive care is therefore more useful than treating every reported recovery as the same clinical event.
| Care approach | Primary aim | Evidence for long COVID | Typical Australian access |
|---|---|---|---|
| Experimental cell-based therapy | Modulate immune activity and potentially support tissue repair | Early patient reports and limited studies; controlled trials are needed | Specialist trials or regulated private programmes |
| Multidisciplinary rehabilitation | Improve function, pacing, sleep and daily activity | Supported as a core component of long-COVID care | Public and private specialists, including GPs and allied health teams |
| Symptom-directed treatment | Address specific issues such as pain, sleep or breathing difficulties | Evidence varies by symptom but remains the usual first line | Medicare-subsidised consultations and prescribed medicines |
| Structured monitoring | Track symptoms, function, oxygen levels and treatment effects | Useful for clinical assessment and research | Chronic-disease management and specialist follow-up |
Early patient accounts can reveal which symptoms deserve investigation and help researchers identify promising treatment signals. They cannot, by themselves, separate the biological effect of the cells from improvements associated with rest, rehabilitation, placebo effects, concurrent treatment or the natural fluctuation of a relapsing condition.
Many experimental programmes use mesenchymal stromal cells, sometimes described as stem cells. These cells are different from embryonic stem cells and are generally not intended to replace whole organs. Instead, researchers believe they may alter the immune environment and influence signals involved in inflammation, blood-vessel formation and tissue recovery.
One proposed mechanism is immunomodulation. Persistent immune activation and microvascular abnormalities are being studied as possible contributors to fatigue, brain fog and breathlessness. Cell-derived signalling molecules might calm inappropriate inflammatory responses, although laboratory findings do not automatically translate into an effective treatment for long COVID.
Other researchers are investigating whether the cells support mitochondrial function, circulation or repair of tissues affected during acute infection. Some protocols use cells collected from a patient, while others use donor-derived material. The manufacturing process, number of infusions, clinical endpoints and length of follow-up can differ substantially, making it difficult to compare one programme with another.
The term “stem cell treatment” also covers products with very different levels of scientific and regulatory scrutiny. A programme that publishes its protocol, tests a defined product and monitors participants is more informative than a clinic offering the same label without accessible data. The biological mechanism remains a hypothesis until controlled clinical evidence supports it.
Improvement accounts have centred on several symptoms commonly associated with post-viral illness. Some participants describe less post-exertional malaise, longer periods of useful activity, reduced breathlessness, better sleep or improved concentration. For people who had been unable to work, walk or manage household tasks, even a modest change can be substantial.
The scale of the perceived recovery also matters. A patient may report being able to walk farther without a later crash, completing a full school or work day, or recovering more quickly after physical activity. These functional gains may be more meaningful to patients than a small change measured on a laboratory scale, although they need consistent assessment over time.
Researchers should record both subjective and objective outcomes. Symptom questionnaires, fatigue scores, cognitive testing, six-minute walk results, oxygen saturation and spirometry can help determine whether reported changes are supported by measurable improvement. Follow-up at 12 months or longer is especially important because a short-lived benefit may not address a chronic condition.
Individual variation is another central feature. Patients with different symptoms, degrees of organ injury and medical histories may respond differently. A result in a small group of highly selected participants cannot automatically be applied to the wider population of people with long COVID.
The current evidence needs to move from compelling accounts to a design capable of testing the treatment fairly. That means randomised controlled trials, consistent eligibility criteria, comparison groups and outcomes selected before results are examined. Blinding may be difficult when treatment involves infusions, but objective measures and independent assessment can reduce bias.
Safety depends heavily on what is being administered. Possible complications include fever, nausea, infection, allergic reactions, blood clots and abnormal immune responses. Risks differ between carefully manufactured stromal cells and poorly characterised products containing immature cells, for which tumour formation is a particular concern. Long-term monitoring is needed even when short-term reports appear favourable.
Manufacturing standards are equally important. Researchers need to know how cells were sourced, isolated, expanded, stored and tested for sterility, potency and genetic stability. Traceability should allow every dose to be linked to its donor or manufacturing batch. General readers can monitor wider biomedical developments through JMA Wired, although original trial records, regulator notices and peer-reviewed publications should remain the primary sources for treatment decisions.
There is currently no Australian approval for a stem-cell product specifically as a treatment for long COVID. The Canberra-based Therapeutic Goods Administration regulates therapeutic goods, while experimental treatment may be available through an approved clinical trial or an individual supply pathway. Protocols should be listed on the Australian Clinical Trials Registry and supported by relevant ethics and regulatory oversight.
Patients in Melbourne and Sydney may encounter private cell-therapy clinics as well as major public research programmes, while those in Brisbane, Adelaide or Perth may need a tertiary referral or travel to participate in a trial. Medicare generally supports ordinary consultations and evidence-based treatment rather than experimental infusions, and private insurance coverage varies. Australian Border Force also applies customs controls to biological material, so anyone considering overseas treatment should check visa, medical-import and sample-transport rules rather than attempting to bring unlabelled biological products into the country.
The pandemic continues to change, and new outbreaks can produce another wave of people with post-viral symptoms. The situation is already being monitored across several countries. Reports from Brazil describe a resurgence attributed to a new variant from the Amazon, highlighting the continuing potential for reinfection and associated long-term illness.
Australia’s existing public-health systems remain relevant to that challenge. Vaccination, timely testing, infection control and access to rehabilitation can reduce the number of people entering acute illness and support those who develop persistent symptoms. State health services in New South South Wales, Victoria, Queensland and Western Australia also continue to refine pathways for complex post-COVID care.
Australia has a growing local market in cell manufacturing, biotechnology and clinical research, including companies that could eventually supply standardised therapies if stronger evidence emerges. Commercial activity does not itself prove clinical effectiveness, however, and patient testimonials should never be treated as an investment signal or a substitute for trial data. Until controlled studies demonstrate a reproducible benefit with an acceptable risk profile, the improvements reported by patients remain an important signal for research rather than proof of an established cure.